Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-2A adrenergic receptor is a subtype of alpha-2 adrenergic receptors, which are G protein-coupled receptors predominantly located in the central nervous system, including the brainstem (notably the locus coeruleus), hypothalamus, hippocampus, cortex, and spinal cord[1][4]. It mediates the inhibitory effects of endogenous catecholamines (norepinephrine and epinephrine) on neurotransmitter release via presynaptic negative feedback, leading to decreased sympathetic outflow, sedation, analgesia, and reduction of blood pressure and heart rate. This receptor is a key pharmacological and therapeutic target for medications providing sedation, treating hypertension, and managing withdrawal symptoms, but is also associated with side effects such as hypotension and sedation[3][4][5].
Agonists: Inhibition of norepinephrine release via presynaptic negative feedback, leading to sedation, analgesia, lowering of blood pressure and heart rate through reduced sympathetic outflow[1][4]. Antagonists: Block presynaptic inhibition, increase norepinephrine release, and may increase sympathetic tone[1][3].
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-2A adrenergic receptor (central) (α2A-AR).